Inform Genomics Announces Results of Study Predicting Risk of Oral Mucositis ... MarketWatch (press release) When commercialized, this product will be available for the hematology oncology stem cell transplant market and will complement the target market of our lead product, OnPART(TM) for patients with solid tumors." The principal investigator for the study, ... |
